Trastuzumab deruxtecan

Unassigned

New Medicines

Metastatic breast cancer, HER2-positive

Information

New molecular entity
Daiichi Sankyo
Daiichi Sankyo

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Antibody-drug conjugate composed of an anti-HER2 antibody, trastuzumab, and a DNA topoisomerase I inhibitor, a DX 8951 derivative. The HER2 antibody is attached to the topoisomerase I inhibitor by a tetrapeptide linker.
In 2014, there were approximately 46,500 new diagnoses of breast cancer in England. It is estimated that approximately 15-25% of women with breast cancer will have HER2-positive tumours [1].
Metastatic breast cancer, HER2-positive
Intravenous infusion

Evidence based evaluations

Metastatic HER2-low breast cancer

Information

Licence extension / variation
Daiichi Sankyo
Daiichi Sankyo

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Phase III Clinical Trials
In 2014, there were approximately 46,500 new diagnoses of breast cancer in England. It is estimated that approximately 15-25% of women with breast cancer will have HER2-positive tumours [1].
Metastatic HER2-low breast cancer
Intravenous infusion